[AWMF-guideline: cocaine-, amphetamine-, ecstasy- and hallucinogen-related disorders].
Actually, guidelines for treatment of substance-related disorders were written under the overall control of the DG-Sucht e. V. and the DGPPN e. V. This appears within the framework of the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaft (AWMF). The leading objective of these guidelines is the description of the current scientifically proven and evidence-based medicine in addiction to derive recommendations to therapy. In this context, the guideline for treatment of cocaine-, amphetamine-, ecstasy-, and halluzinogen-related disorders is introduced.
Thomasius
R
R
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf. thomasius@uke.uni-hamburug.de
Gouzoulis-Mayfrank
E
E
Karus
C
C
Wiedenmann
H
H
Hermle
L
L
Sack
P M
PM
Zeichner
D
D
Küstner
U
U
Schindler
A
A
Krüger
A
A
Uhlmann
S
S
Petersen
K U
KU
Zapletalova
P
P
Wartberg
L
L
Schütz
C G
CG
Schulte-Markwort
M
M
Obrocki
J
J
Heinz
A
A
Schmoldt
A
A
D000328:Adult; D019969:Amphetamine-Related Disorders / Q000628:therapy*; D019970:Cocaine-Related Disorders / Q000628:therapy*; D015897:Comorbidity; D019317:Evidence-Based Medicine; D005260:Female; D006213:Hallucinogens; D006801:Humans; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D011247:Pregnancy; D019966:Substance-Related Disorders / Q000503:physiopathology / Q000628:therapy*
D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine